Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. 2013

Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
Center for Infectious and Inflammatory Disease, Institute of Bioscience and Technology, Texas A&M University Health Science Center, Houston, Texas, United States of America.

Upon contact with human plasma, bacteria are rapidly recognized by the complement system that labels their surface for uptake and clearance by phagocytic cells. Staphylococcus aureus secretes the 16 kD Extracellular fibrinogen binding protein (Efb) that binds two different plasma proteins using separate domains: the Efb N-terminus binds to fibrinogen, while the C-terminus binds complement C3. In this study, we show that Efb blocks phagocytosis of S. aureus by human neutrophils. In vitro, we demonstrate that Efb blocks phagocytosis in plasma and in human whole blood. Using a mouse peritonitis model we show that Efb effectively blocks phagocytosis in vivo, either as a purified protein or when produced endogenously by S. aureus. Mutational analysis revealed that Efb requires both its fibrinogen and complement binding residues for phagocytic escape. Using confocal and transmission electron microscopy we show that Efb attracts fibrinogen to the surface of complement-labeled S. aureus generating a 'capsule'-like shield. This thick layer of fibrinogen shields both surface-bound C3b and antibodies from recognition by phagocytic receptors. This information is critical for future vaccination attempts, since opsonizing antibodies may not function in the presence of Efb. Altogether we discover that Efb from S. aureus uniquely escapes phagocytosis by forming a bridge between a complement and coagulation protein.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
September 2013, Journal of immunology (Baltimore, Md. : 1950),
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
April 2010, Infection and immunity,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
November 2005, The Journal of laboratory and clinical medicine,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
March 2002, The Journal of biological chemistry,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
January 2013, Results in immunology,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
September 2009, Veterinary microbiology,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
January 1987, Chemotherapy,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
July 2019, Microbiology spectrum,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
January 1988, Reviews of infectious diseases,
Ya-Ping Ko, and Annemarie Kuipers, and Claudia M Freitag, and Ilse Jongerius, and Eva Medina, and Willemien J van Rooijen, and András N Spaan, and Kok P M van Kessel, and Magnus Höök, and Suzan H M Rooijakkers
August 2004, The Journal of infectious diseases,
Copied contents to your clipboard!